Current Overview on the Usage of Poly(ADP-ribose)polymerase (PARP) Inhibitors in Treating Cancer

Publisher： Bentham Science Publishers

E-ISSN： 2212-6988|1|2|127-148

ISSN： 2212-697x

Source： Clinical Cancer Drugs, Vol.1, Iss.2, 2014-05, pp. : 127-148

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Current Overview on the Usage of Poly(ADP-ribose)polymerase (PARP) Inhibitors in Treating Cancer

By  

Clinical Cancer Drugs, Vol. 1, Iss. 2, 2014-01 ,pp. : 127-148

Bentham Science Publishers

Access to resources Recommend Favorite

New inhibitors of poly(ADP-ribose) polymerase (PARP)

By Peukert Stefan   Schwahn Uwe  

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 11, 2004-11 ,pp. : 1531-1551

Informa Healthcare

Access to resources Recommend Favorite

Poly(ADP-Ribose) Polymerase Inhibitors

By  

Current Medicinal Chemistry, Vol. 10, Iss. 4, 2003-01 ,pp. : 321-340

Bentham Science Publishers

Access to resources Recommend Favorite

Structure, Function and Inhibition of Poly(ADP-ribose)polymerase, Member 14 (PARP14)

By  

Mini Reviews in Medicinal Chemistry, Vol. 18, Iss. 19, 2018-11 ,pp. : 1659-1669

Bentham Science Publishers

Access to resources Recommend Favorite

The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer Treatment

By  

Current Drug Targets, Vol. 12, Iss. 14, 2011-01 ,pp. : 2034-2044

Bentham Science Publishers

Access to resources Recommend Favorite